Yükleniyor... / Loading...
This study evaluates the use of a blood (plasma) next-generation sequencing (NGS) test in patients with ALK-positive advanced non-small cell lung cancer who develop resistance to ALK-targeted therapy. It included patients over 18 whose disease progressed while on a next-generation ALK inhibitor. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Men or women older than 18 years at the time of consent. * Demonstration of having advanced ALK positive NSCLC. * Systemic progression (not CNS only progression) within the past 30 days while receiving a next generation ALK TKI. * Patient must not have started a new line of therapy before signing the informed consent form. * Willingness to provide a blood specimen prior to the initiation of a new line of treatment. * Willing to provide clinical and medical information to the study team as required. * Ability to read, write and communicate in English. * Ability to sign a web-based informed consent form. Exclusion Criteria: * Participants who are unable to provide informed consent. * Participants who are 18 years of age or younger. * Participants who are unable to comply with the study procedures. * Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements. * Participants who have previously enrolled to the study